NCT00535080No Longer Available不适用
Compassionate Use of Metvix® (Methyl Aminolevulinate) PDT in Subjects With Field Actinic Keratoses, Large/Multiple Superficial BCCs, or Bowen's Disease
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- Galderma R&D
研究概览
简要总结
The aim of this study is to provide this investigational drug to patients who cannot be optimally treated with conventional therapies and to collect efficacy and safety data on the use of Metvix PDT in subjects with field actinic keratoses, large/multiple superficial basal cell carcinomas (BCCs) or Bowen's disease.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subject older than 18 years.
- •Subject presenting with:
- •Either field actinic keratoses (AKs) (mild to moderate, multiple and clustered AKs on a severely sun-damaged skin); or
- •Biopsy-confirmed large, or multiple (several in the same anatomical area) primary superficial BCC lesions that are macroscopically and histologically consistent with superficial basal cell carcinoma (sBCC) and have no histological evidence of aggressive growth patterns; or
- •Histologically confirmed diagnosis of Bowen's disease from a biopsy taken within 3 months
- •Any subject presenting with the aforementioned lesions must not be able to be treated optimally by conventional therapies.
- •Female subject of childbearing potential, using an effective birth control method (see Case Report Form) and having a negative pregnancy test at the beginning of the study, or female subject of non childbearing potential
- •Subject must be willing and capable of cooperating to the extent and degree required by the protocol.
- •Subject has to read Patient Information Sheet and read and sign the Informed Consent form prior to any study related procedure.
排除标准
- •A recurrent superficial BCC lesion that has previously been treated.
- •Subject whose lesions on the selected treatment zone (including a 5 cm margin around the treatment area) have been treated with any of the following topical treatments within the specified washout period:
- •5-FU - 3 months
- •Cryotherapy - 3 months
- •Imiquimod - 3 months
- •PDT - 3 months
- •Diclofenac sodium - 3 months
- •Surgery, radiotherapy, curettage, electrodesiccation, retinoids, dermabrasion, laser resurfacing, salicylic acid - 3 months
- •A primary superficial BCC located close to or involving a scar of SCC
- •Subject with known porphyria.
- •Subject with target lesions on the genitals.
- •Subject with known xeroderma pigmentosum.
- •Pigmented lesion(s) on the treated area.
- •Morpheaform lesion(s) on the treated area.
- •Infiltrating lesion(s) on the treated area.
- •Female subject who is pregnant, nursing or planning a pregnancy during the study.
- •Subject with known hypersensitivity to methyl 5-aminolevulinate, a similar compound or excipients of the cream.
- •Subject who has participated in another investigational drug or device research study within 30 days of enrolment.
研究者
相似试验
终止
3 期
Daptomycin for the Treatment of Infections Due to Gram-Positive BacteriaGram-Positive Bacterial InfectionsNCT00055198Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)75
已完成
1 期
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal TumorsNeuroectodermal Tumor, PrimitiveNeuroepitheliomaOsteosarcomaSarcoma, Ewing'sSarcomaNCT00001209National Cancer Institute (NCI)120
Unknown
2 期
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaMinimal Residual DiseaseNCT05362942Beijing 302 Hospital52
撤回
3 期
Maraviroc Compassionate UseHuman Immunodeficiency Virus Type 1NCT00719823ViiV Healthcare
已完成
2 期
Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMDMacular Degeneration, Age-RelatedDry Macular DegenerationGeographic AtrophyAge-Related Macular DegenerationNCT02684578University of California, San Francisco66